Serum Ferritin Levels in Alzheimer's Disease: A Meta-Analysis (Preprint)

2020 ◽  
Author(s):  
Praveen Parthasarathy
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Iron Overload ◽  
Serum Ferritin ◽  
Meta Analysis ◽  
Iron Storage ◽  
Blood Biomarker ◽  
Pubmed Database ◽  
Healthy Control

BACKGROUND The role of iron overload in Alzheimer’s Disease (AD) pathology has been investigated in previous years, but mechanisms underlying overload remain unclear. Ferritin is an iron storage and transport protein that has been associated with inflammation and neurodegenerative disease. OBJECTIVE The objective of this study was to evaluate if serum ferritin levels in AD subjects are significantly higher than serum ferritin levels among a healthy control. METHODS A systematic literature search of the PubMed database yielded fifty publications, culminating in two studies that were used in statistical analysis. RESULTS Our results showed that pooled serum ferritin levels were significantly higher in AD patients than in healthy controls [SMD: 1.06, 95 % CI: (0.68, 1.43), z = 5.53, p ≈ 0.00]. CONCLUSIONS Findings from this study suggest that serum ferritin may be a potent blood biomarker for AD. Research must be conducted to further evaluate the role of serum ferritin as a neurotoxic, neuroprotective, or an indicator molecule in AD pathology. We propose that increased serum ferritin levels in AD may contribute to neuroinflammation and iron overload in neuroglia.

scholarly journals Multi-regional Neurodegeneration in Alzheimer’s disease: Meta-analysis and data integration of transcriptomics data

2018 ◽  
Author(s):  
Karbalaei Reza ◽  
Rezaei-Tavirani Mostafa ◽  
Torkzaban Bahareh ◽  
Azimzadeh Sadegh
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Metabolic Pathways ◽  
Analytical Study ◽  
Meta Analysis ◽  
Brain Regions ◽  
Regulatory Pathways ◽  
Transcriptomics Data ◽  
The Brain

AbstractAlzheimer’s disease (AD) is a complex neurodegenerative disease with various deleterious perturbations in regulatory pathways of various brain regions. Thus, it would be critical to understanding the role of different regions of the brain in initiation and progression of AD, However, owing to complex and multifactorial nature of this disease, the molecular mechanism of AD has yet to be fully elucidated. To confront with this challenge, we launched a meta-analytical study of current transcriptomics data in four different regions of the brain in AD (Entorhinal, Hippocampus, Temporal and Frontal) with systems analysis of identifying involved signaling and metabolic pathways. We found different regulatory patterns in Entorhinal and Hippocampus regions to be associated with progression of AD. We also identified shared versus unique biological pathways and critical proteins among different brain regions. ACACB, GAPDH, ACLY, and EGFR were the most important proteins in Entorhinal, Frontal, Hippocampus and Temporal regions, respectively. Moreover, eight proteins including CDK5, ATP5G1, DNM1, GNG3, AP2M1, ALDOA, GPI, and TPI1 were differentially expressed in all four brain regions, among which, CDK5 and ATP5G1 were enriched in KEGG Alzheimer’s disease pathway as well.

scholarly journals Biomarkers in Alzheimer’s disease

2021 ◽  
Author(s):  
Larissa Maria de Paula Rebouças da Costa ◽  
Gabriel de Souza Torres ◽  
Kauan Alves Sousa Madruga ◽  
Poliana Rafaela dos Santos
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Low Cost ◽  
Meta Analysis ◽  
Diagnostic Biomarkers ◽  
Non Invasive ◽  
Blood Tests ◽  
Pubmed Database ◽  
Amyloid Aβ ◽  
Phosphorylated Tau Protein

Background: Alzheimer’s disease (AD) is the most common cause of dementia and cognitive dysfunction in old ages. AD is characterised by beta- amyloid (Aβ) plaques and neurofibrillary tangles of the hyper-phosphorylated Tau protein. It has an extensive preclinical stage, which emphasizes the importance of the biological components related to an early diagnostic: biomarkers. Objectives: After critical analysis of the selected literature, this review has the goal of describing the main biomarkers in AD and discussing different ways of detecting it. Methods: This review was elaborated after a literature review in the PubMed database, with 15 articles published between 2016 and 2021. The keywords were used with the boolean operator “AND”. Articles of meta-analysis, review and systematic review were selected. Results: It was found central biomarkers for the AD diagnostic, such as Tau and Aβ. The following tests were used: CSF puncture; blood tests; neuroimaging; saliva and mucosa samples. Aβ and Tau can be collected by CSF or PET-TC. Conclusions: Biomarkers play an important role in early AD diagnostic, even with limitations in the tests. The CSF and PET-TC are expensive methods, only used in atypical cases of AD. Reliable blood tests remain in development. In conclusion, there’s the need for more studies about alternative diagnostic tests, that are non-invasive and have low cost. Those developments can be beneficial for health plans, helping early diagnosis of AD.

Anosognosia in Alzheimer’s disease: The role of impairment levels in assessment of insight across domains

2010 ◽  
Vol 16 (3) ◽  
pp. 463-473 ◽  
Author(s):  
HANNA LEICHT ◽  
MARTIN BERWIG ◽  
HERMANN-JOSEF GERTZ
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Neuropsychological Tests ◽  
Control Sample ◽  
Self Assessment ◽  
Domain Specific ◽  
Clinical Rating ◽  
Healthy Control ◽  
And Performance

AbstractImpaired insight for deficits (anosognosia) is common in Alzheimer’s disease (AD). However, it has not yet been determined clearly (a) whether different methods for assessing insight are comparable, and (b) whether anosognosia affects different domains to different degrees (domain-specificity). Impaired insight was investigated in 32 patients with AD, who were each accompanied by a caregiver. Anosognosia was assessed by a global clinical rating, questionnaire discrepancies (patient vs. caregiver) covering different domains, and performance discrepancies (self-assessment vs. performance) based on four neuropsychological tests which were compared with those of a healthy control sample. The results of clinical rating and questionnaire discrepancies were closely correlated, but performance discrepancies showed no association with the other methods. Anosognosia was present in the majority of the sample, and occurred across domains. The domains corresponding to core deficits in AD (recent memory, activities of daily living) appeared especially prone to anosognosia. However, results do not suggest that anosognosia itself is domain-specific. Rather, it appears that insight may be invariant, while differences in patient-caregiver discrepancies arise largely from different degrees of deficit across domains. (JINS, 2010, 16, 463–473.)

scholarly journals The Role of Peripheral Inflammatory Markers in Dementia and Alzheimer's Disease: A Meta-Analysis

2012 ◽  
Vol 68 (4) ◽  
pp. 433-440 ◽  
Author(s):  
A. Koyama ◽  
J. O'Brien ◽  
J. Weuve ◽  
D. Blacker ◽  
A. L. Metti ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Inflammatory Markers ◽  
Meta Analysis

scholarly journals Decreased Serum Brain-Derived Neurotrophic Factor (BDNF) Levels in Patients with Alzheimer’s Disease (AD): A Systematic Review and Meta-Analysis

2019 ◽  
Vol 20 (2) ◽  
pp. 257 ◽  
Author(s):  
Ted Ng ◽  
Cyrus Ho ◽  
Wilson Tam ◽  
Ee Kua ◽  
Roger Ho
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Neurotrophic Factor ◽  
Molecular Mechanisms ◽  
Meta Analysis ◽  
Brain Derived Neurotrophic Factor ◽  
Significant Heterogeneity ◽  
Healthy Controls ◽  
Healthy Control ◽  
Serum Bdnf

Findings from previous studies reporting the levels of serum brain-derived neurotrophic factor (BDNF) in patients with Alzheimer’s disease (AD) and individuals with mild cognitive impairment (MCI) have been conflicting. Hence, we performed a meta-analysis to examine the aggregate levels of serum BDNF in patients with AD and individuals with MCI, in comparison with healthy controls. Fifteen studies were included for the comparison between AD and healthy control (HC) (n = 2067). Serum BDNF levels were significantly lower in patients with AD (SMD: −0.282; 95% confidence interval [CI]: −0.535 to −0.028; significant heterogeneity: I2 = 83.962). Meta-regression identified age (p < 0.001) and MMSE scores (p < 0.001) to be the significant moderators that could explain the heterogeneity in findings in these studies. Additionally, there were no significant differences in serum BDNF levels between patients with AD and MCI (eight studies, n = 906) and between MCI and HC (nine studies, n = 5090). In all, patients with AD, but not MCI, have significantly lower serum BDNF levels compared to healthy controls. This meta-analysis confirmed the direction of change in serum BDNF levels in dementia. This finding suggests that a significant change in peripheral BDNF levels can only be detected at the late stage of the dementia spectrum. Molecular mechanisms, implications on interventional trials, and future directions for studies examining BDNF in dementia were discussed.

Sign in / Sign up

Export Citation Format

Share Document